Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 824

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 824
---
 |               42 |     |    — |
| NLS Current account**           |     |              400 |     |    — |
| Employees and payroll accruals* |     |              163 |     |  226 |
|                                 |     |              605 |     |  226 |

____________ * Includes a bonus in the amount of USD $82 thousand in respect of a liability to related parties (see Note 22). ** A total of NIS 1,496 thousand (USD $400 thousand) was received on November 20, 2024 from the Swiss biopharmaceutical company NLS Pharmaceutics Ltd (“NLS”). This amount represents a current account between the Company and NLS intended for the settlement of future shared costs related to the merger transaction. The unused balance of the current account will be settled upon completion of the merger.

Annex G-19

KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 12: — CONTINGENT liabilities to the Innovation Authority in respect of royalties A.The Company received grants from the government of Israel for participation in research and development, and in exchange, it committed to pay royalties at a rate of 3% from sales of the research and development outcomes that were funded up to the total grants received, dollar -linkedand plus interest at the LIBOR interest (see Note 2C). B.On March 2, 2022, the Company received the approval of the IIA to receive a support grant for a total budget of USD $3 million (NIS 10 million) (hereinafter, the “Budget”), for the purpose of a plan to continue the development of cellular therapy to treat ALS. The IIA’s participation will be at a rate of 40% of the total Budget. As of the date of the financial statements, the Company received USD $1,030 thousands from this amount. The total grants received from the National Authority for Technological Innovation by December 31, 2024, for which the Company is contingently liable to pay future royalties, was USD $14,209 thousand. As of the date of the financial statements, the Company does not recognize a liability to the IIA, as it does not anticipate having revenues in the foreseeable future. Note 13: — Financial Instruments A. Financial assets Below is a classification of the financial assets and financial liabilities in the financial statements for the financial instrument categories in accordance with IFRS 9:

|                                     |